Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) face a high risk of hyperkalemia.
• Hyperkalemia can increase mortality and necessitate dose reduction or discontinuation of renin-angiotensin-aldosterone system inhibitors (RAASi).
• Patiromer, a non-absorbed potassium binder, is a potential therapeutic option for managing hyperkalemia in CKD patients on RAASi.

Purpose of the Study:

• To determine the onset of action of patiromer in patients with CKD and hyperkalemia who are taking at least one RAASi.
• To evaluate the efficacy and tolerability of patiromer in reducing serum potassium levels.

Main Methods:

• Following a 3-day potassium- and sodium-restricted diet, patients with sustained hyperkalemia (serum potassium 5.5–6.5 mEq/L) received oral patiromer (8.4 g/dose) twice daily with meals for four doses.
• Serum potassium levels were monitored at multiple time points from baseline up to 48 hours after the last dose, including during outpatient follow-up.

Main Results:

• Mean serum potassium was significantly reduced by 7 hours after the first dose and remained reduced throughout the 48-hour study period.
• Therapeutic serum potassium levels (<5.5 mEq/L) were achieved within 20 hours.
• A significant mean reduction of 0.75 mEq/L in serum potassium was observed at 48 hours.
• Patiromer was well tolerated, with mild constipation as the most common adverse event; no hypokalemia was reported.

Conclusions:

• Patiromer demonstrates an early and sustained reduction in serum potassium levels in patients with CKD and hyperkalemia on RAASi.
• Patiromer is well-tolerated and offers a safe option for managing hyperkalemia, potentially allowing continued RAASi therapy.